215 cases of adverse drug reactions related to small molecule kinase inhibitors

doi:10.19803/j.1672-8629.2022.05.16

Abstract

Abstract: Objective To investigate the characteristics of adverse drug reaction (ADR) related to small molecule kinase inhibitors (SMKIs), and provide reference for safe and rational use of drugs. Methods The medical records of inpatients in our hospital who had developed ADR after SMKI treatments between October 1st 2012 and April 30th 2019 were collected and reviewed. The demographics of patients, suspected drug use and clinical characteristics of ADR were analyzed. Results A total of 215 patients developed ADR secondary to SMKI treatments. The ratio of males to females was 1.29∶1 and the average age was 58.91±13.75 years. Seventeen types of SMKIs were involved, and the top five were erlotinib (20.47%), gifitinib (16.74%), sunitinib (14.42%), imatinib (12.56%) and sorafenib (12.09%) according to the proportions of ADR. Multiple systems-organs were implicated in ADR related to SMKIs, and impairments in the skin and its accessories (35.62%) and in the digestive system (31.05%) weres prevalent. Most of these cases were common ADR, but there were severe ones that led to drug discontinuation. Conclusion SMKI-related ADR can possibly involve multiple systems/organs. Close monitoring, early detection and intervention are required to improve patients' compliance and clinical efficacy of targeted therapies.

Key words: targeted drug, small molecule kinase inhibitor, adverse drug reaction

CLC Number:

R994.11

FAN Qianqian, ZHANG Bo, ZHAO Bin, LI Qiuyue, LIU Fang, MA Jie. 215 cases of adverse drug reactions related to small molecule kinase inhibitors[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 550-553.

References

[1] ROBERT R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a2020 update[J]. Pharmacol Res, 2020(152): 104609.
[2] CHEN M, CHEN XW, HONG XH, et al.Application of small molecule protein kinase inhibitors in tumor therapy[J]. Chinese Journal of Clinical Oncology(中国肿瘤临床), 2020, 47(10): 523-529.
[3] HABRE M, SALLOUM A, HABRE SB, et al.Skin adverse events in recently approved targeted therapies in solid malignancies[J]. Future Oncol, 2019, 15(3): 331-343.
[4] VAN SEBILLE YZ, GIBSON RJ, WARDILL HR, et al.Gastrointe-stinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer[J]. Curr Opin Support Palliat Care, 2016, 10(2): 152-156.
[5] DAMRONGWATA NA SU K R , Frad ley MG. Ca r d iova scu la r complications of targeted therapies for chronic myeloid leukemia[J]. Curr Treat Options Cardiovasc Med, 2017, 19(4): 24.
[6] YANG H, WEI J, WANG JY, et al.Study on methods of adverse drug reaction/event reporting assessment[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2009, 6(10): 581-584.
[7] N ational M edical P roducts A dministration. M easures f or t he reporting and monitoring of adverse drug reaction(Decree No. 81 of the Ministry of Health) [EB/OL]. (2011-05-04) [2020-09-18]. https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20110504162501325_7.html.
[8] ZHENG SR, SUN K X, ZHANG SW, et al.Report of cancer epidemiology in China, 2015[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2019, 41(1): 19-28.
[9] PAN F.Tumor molecular typing and targeted therapy are the frontiers of future research-interview with Professor Wu Yilong, Director of the National Lung Cancer Quality Control Center[J]. China Medical Herald(中国医药导报), 2019, 16(4): 1-3.
[10] MACDONALD JB, MACDONALD B, GOLITZ LE, et al.Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane[J]. J Am AcadDermatol, 2015, 72(2): 203-218.
[11] LI HY, YANG CP, JIN HT.Research progress of target related toxicity of anti-tumor drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(3): 152-157.
[12] FIALA O, PESEK M, FINEK J, et al.Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice[J]. Neoplasma, 2013, 60(1): 26-32.
[13] XIE XD, GUO F. Further discussion on the research progress of cutaneous toxicities of anti-tumor molecular targeted drugs[C]. Proceedings of the 9th Chinese Symposium on Medical Oncology, the 4th Annual Meeting of Chinese Society for Clinical Oncologists,the2015 Annual Meeting of Clinical Cancer Chemotherapy Committee of China Anti Cancer Association(第九届中国肿瘤内科大会、第四届中国肿瘤医师大会、中国抗癌协会肿瘤临床化疗专业委员会2015 年学术年会论文集). 2015.
[14] LIU S, KURZROCK R.Understanding toxicities of targeted agents: implications for anti-tumor activity and management[J]. Semin Oncol, 2015, 42(6): 863-875.
[15] SHAH DR, SHAH RR, MORGANROTH J.Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy[J]. Drug Saf, 2013, 36(6): 413-426.
[16] SHI Q, YANG X, REN L, et al.Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors[J]. Expert Opin Drug Metab Toxicol, 2020, 16(3): 217-226.
[17] FUNAKOSHI T, LATIF A, GALSKY MD.Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis[J]. Cancer Treat Rev, 2013, 39(7): 818-830.
[18] JIANG Q, CHEN SS, JIANG B, et al.Relationship between cytopenia and cytogenetic response in imatinib mesylate treated Ph-positive chronic myeloid leukemia in chronic phase patients[J]. Journal of Peking University (Health Sciences) [ 北京大学学报(医学版)], 2003, 35(2): 136-140.
[19] PORTA C, COSMAI L, GALLIENI M, et al.Renal effects of targeted anticancer therapies[J]. Nat Rev Nephrol, 2015, 11(6): 354-370.
[20] HAYMAN SR, LEUNG N, GRANDE JP, et al.VEGF inhibition, hypertension, and renal toxicity[J]. Curr Oncol Rep, 2012, 14(4): 285-294.
[21] PORTA C, COSMAI L, GALLIENI M, et al.Renal effects of targeted anticancer therapies[J]. Nat Rev Nephrol, 2015, 11(6): 354-370.
[22] FAN QQ, ZHANG B, ZHAO B, et al.Advances in research on nephrotoxicity of small molecule kinase inhibitors[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2020, 29(3): 206-211.